JM
Journey Medical Corp (DERM)·Q2 2025 Earnings Summary
Executive Summary
- Q2 2025 revenue was $15.009M, a modest beat vs S&P Global consensus ($14.804M*) driven by Emrosi’s first full quarter ($2.8M) and offset by Accutane’s $2.3M YoY decline; EPS was $(0.16), missing consensus ($(0.105)*) as SG&A rose with launch investment .
- Gross margin expanded to 67% (from 64% in Q1 and 61% in Q2 2024) on favorable mix as Emrosi is a low-cost product, establishing a higher baseline margin trajectory .
- Management withheld formal financial guidance, reiterating the goal to achieve sustainable positive EBITDA later in 2025; payer coverage for Emrosi accelerated to ~65% of commercial lives by July vs 30% in Q1, a key ramp driver .
- Call highlights: early Emrosi adoption (10% NRx share among targeted derm prescribers in June), strong refill trends, and QBREXZA revenue of $6.9M in Q2; management cautioned against simple ASP per script math given coupons and reimbursement lags .
- Visibility catalysts include Russell 2000/3000 index inclusion in June and the Nasdaq closing bell event, supporting investor awareness amid the Emrosi launch ramp .
What Went Well and What Went Wrong
What Went Well
- Emrosi delivered $2.8M net sales in its first full quarter; prescriptions set new highs weekly/monthly, achieving >10% share of new prescriptions among targeted dermatology writers by June .
- Payer coverage rapidly expanded from ~30% in May to ~65% in July, enabling greater conversion of prescription demand into revenue over coming quarters .
- Gross margin improved to 67%, with CFO noting Emrosi’s low COGS and mix benefits create a reasonable baseline and room for further improvement as Emrosi becomes a larger percentage of sales .
Management quotes:
- “We have now seen over 1,800 unique prescribers…a testament to the effectiveness of our commercial team and the unmet need Emrosi is addressing.”
- “Product mix is really the driver of the gross margin…as Emrosi becomes a larger percent…we expect the margins to improve.”
- “We believe Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond.”
What Went Wrong
- Accutane revenue declined $2.3M due to aggressive generic pricing (Mayne, Zydus), pressuring legacy portfolio contributions .
- EPS missed consensus (loss $(0.16) vs $(0.105)*), reflecting higher SG&A (+$1.6M YoY to $11.9M) tied to Emrosi commercialization and increased interest expense .
- No formal FY25 guidance provided; management intends to wait “a few more quarters,” limiting near-term visibility despite launch momentum .
Financial Results
Multi-period comparatives
Actual vs S&P Global consensus
Values with * retrieved from S&P Global.
Values with * retrieved from S&P Global.
Product contribution (Q2 2025)
KPIs and balance sheet indicators
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “We expect to build on this momentum…Ambrosi will generate high contribution margins and provide significant leverage toward our overall profitability and growth.” — CEO Claude Maraoui .
- “We believe it represents a reasonable baseline going forward…as Emrosi becomes a larger percent…we expect the margins to improve.” — CFO Joseph Benesch on gross margins .
- “Delivering cost-effective coverage…our strong progress with payers…ensure that patients receiving a prescription for Emrosi are able to benefit.” — CEO on payer adoption .
- “We believe Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond.” — CEO on outlook .
Q&A Highlights
- Coverage trajectory: Management at ~65% commercial lives; target not disclosed; dual focus on quantity (access) and quality (formulary implementation) to convert demand to revenue .
- Gross margin: CFO emphasized product mix and Emrosi’s low cost underpin margin improvement; expects continued benefits as mix shifts .
- ASP per script: CEO cautioned against simple revenue/TRx math due to coupons and reimbursement timing; no ASP guidance provided .
- Seasonality: CEO expects limited impact near term given early launch dynamics; potential tailwind exiting summer as demand builds .
- QBREXZA performance: CFO disclosed ~$6.9M Q2 revenue, and earlier noted ongoing Rx growth despite competition .
- Stocking/managed care conversion: Early Q1 channel stocking transitioned to pull-through; rebate and coverage dynamics to evolve as more plans implement formulary access .
Estimates Context
- Revenue beat: Q2 2025 actual $15.009M vs consensus $14.804M*; Q1 2025 actual $13.139M vs $12.055M*; Q2 2024 actual $14.855M vs $13.880M* . Values with * retrieved from S&P Global.
- EPS miss: Q2 2025 actual $(0.16) vs consensus $(0.105); Q1 2025 actual $(0.18) vs $(0.238); Q2 2024 actual $(0.17) vs $(0.143)*. Values with * retrieved from S&P Global .
- Consensus coverage: 4 estimates for Q2/Q1 2025; 3 for Q2 2024 on both revenue and EPS* (S&P Global). Values with * retrieved from S&P Global.
Where estimates may adjust:
- Upward revenue revisions likely as coverage and prescriber base scale; margin estimates may lift with mix (Emrosi’s low COGS) .
- EPS path depends on SG&A intensity and interest expense; operating leverage should improve as Emrosi grows and coverage quality (formulary implementation) increases .
Key Takeaways for Investors
- Emrosi’s first full quarter contributed $2.8M; >10% NRx share among target writers; >1,800 unique prescribers—evidence of strong initial adoption and launch execution .
- Revenue beat vs consensus in Q2; EPS miss reflects launch SG&A and interest costs—watch margin trajectory and SG&A discipline as coverage quality ramps . Values with * retrieved from S&P Global.
- Gross margin at 67% sets a higher baseline; CFO sees further mix-driven improvement as Emrosi scales—positive for medium-term profitability .
- Payer coverage rose to ~65% of commercial lives by July; ongoing formulary implementation is key to converting demand to net revenue—near-term trading catalyst as “quality” coverage improves .
- Legacy Accutane remains a headwind ($(2.3)M YoY decline); QBREXZA solid at $6.9M—portfolio mix shifts toward growth brands reduce volatility .
- No formal guidance; management reiterates drive to positive EBITDA in 2025—expect guidance later after more quarters of launch data .
- Visibility catalysts (Russell inclusion, Nasdaq bell) plus accumulating clinical/real-world data (JAMA, SDPA, TV segment) support broader awareness and physician adoption .
Appendix: Additional Data Tables
Income statement detail (company-reported)
Non-GAAP Adjusted EBITDA reconciliation (company-reported)
Notes: Adjusted EBITDA is a non-GAAP measure; see company reconciliation and definitions .
Annual consensus context (S&P Global)
Values with * retrieved from S&P Global.